8-K current report · filed Nov 4, 2026

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1MRVI overview

Short answer

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced by Maravai LifeSciences.

MARAVAI LIFESCIENCES HOLDINGS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced by Maravai LifeSciences
  • Full results, operating metrics and management commentary in Exhibit 99.1
  • Investor focus: quarterly performance trends and updated outlook disclosed in the earnings release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $45.9M, up 10.1% YoY, with TriLink up 11.8% and Cygnus up 7.5%
  • mRNA revenue rose 28%, while four Discovery customers transitioned to clinical-stage GMP, supporting future commercial demand
  • Adjusted EBITDA improved to $5.8M from $(10.8)M, though GAAP net loss remained $(24.0)M
  • Nine-month revenue up 20.1% to $163.1M, including $14.3M of COVID CleanCap orders and 12.9% base TriLink growth excluding them
  • 2026 guidance raised: revenue $212.0M-$216.0M and Adjusted EBITDA $40.0M-$42.0M, versus prior ranges of $205.0M-$215.0M and $33.0M-$35.0M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MARAVAI LIFESCIENCES HOLDINGS, INC. 8-K filings

Get the next MRVI 8-K as it lands

Follow MRVI for push alerts, or ask the research agent what this filing means.